SRI Biosciences’ Center for Cancer and Metabolism is uniquely positioned to discover novel approaches to cancer treatment by integrating basic research with industry-honed discovery and development disciplines.
With a distinguished history of innovative advances in cutting-edge areas of cancer research, through strategic partnerships, SRI discovered two cancer drugs and helped bring them to market:
- Bexarotene (Targretin®), a novel selective retinoid nuclear hormone receptor ligand, is marketed by Eisai for treating cutaneous T-cell lymphoma
- Pralatrexate (FOLOTYN®) is marketed by Allos Therapeutics for the treatment of relapsed or refractory peripheral T-cell lymphoma.
The Center also has a pipeline of compounds in clinical trials and in various stages of discovery and preclinical development.
SRI operates one of seven National Cancer Institute (NCI) funded Tumor Glycome Laboratories. These laboratories are the principal component of the trans-NIH Alliance of Glycobiologists for Detection of Cancer and Cancer Risk, which is searching for glycan-based biomarkers for breast, ovarian, lung, prostate, and pancreatic cancers and melanoma. Learn more about SRI's Tumor Glycome Laboratory.
Our specialized capabilities also include a high-throughput screening core facility.